Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

684 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Intravascular large B cell lymphoma: proposed of the strategy for early diagnosis and treatment of patients with rapid deteriorating condition.
Masaki Y, Dong L, Nakajima A, Iwao H, Miki M, Kurose N, Kinoshita E, Nojima T, Sawaki T, Kawanami T, Tanaka M, Shimoyama K, Kim C, Fukutoku M, Kawabata H, Fukushima T, Hirose Y, Takiguchi T, Konda S, Sugai S, Umehara H. Masaki Y, et al. Among authors: miki m. Int J Hematol. 2009 Jun;89(5):600-10. doi: 10.1007/s12185-009-0304-7. Epub 2009 Apr 14. Int J Hematol. 2009. PMID: 19363707
[Primary neurolymphomatosis of the cervical nerve root].
Miki M, Masaki Y, Nakamura T, Iwao H, Nakajima A, Sakai T, Sawaki T, Kawanami T, Kaito M, Kurose N, Fujita Y, Tanaka M, Fukushima T, Hirose Y, Umehara H. Miki M, et al. Rinsho Ketsueki. 2010 Jul;51(7):564-7. Rinsho Ketsueki. 2010. PMID: 20693778 Japanese.
Efficacy and safety of bortezomib plus dexamethasone therapy for refractory or relapsed multiple myeloma: once-weekly administration of bortezomib may reduce the incidence of gastrointestinal adverse events.
Fukushima T, Nakamura T, Iwao H, Nakajima A, Miki M, Sato T, Sakai T, Sawaki T, Fujita Y, Tanaka M, Masaki Y, Nakajima H, Motoo Y, Umehara H. Fukushima T, et al. Among authors: miki m. Anticancer Res. 2011 Jun;31(6):2297-302. Anticancer Res. 2011. PMID: 21737655
Low-dose cytarabine plus aclarubicin for patients with previously untreated acute myeloid leukemia or high-risk myelodysplastic syndrome ineligible for standard-dose cytarabine plus anthracycline.
Fukushima T, Kawabata H, Sawaki T, Satoh T, Nakamura T, Iwao H, Nakajima A, Sakai T, Miki M, Fujita Y, Tanaka M, Kawanami T, Masaki Y, Okazaki T, Umehara H. Fukushima T, et al. Among authors: miki m. Anticancer Res. 2012 Apr;32(4):1347-53. Anticancer Res. 2012. PMID: 22493369
684 results